Feature

The Alzheimer's gamble

See allHide authors and affiliations

Science  31 Aug 2018:
Vol. 361, Issue 6405, pp. 838-841
DOI: 10.1126/science.361.6405.838

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

  • Who will be suffering from losing the Alzheimer’s gamble?
    • Fumitake Satoh, CEO, Miz Company Limited
    • Other Contributors:
      • Shin-ichi Hirano, researcher, Miz Company Limited
      • Ryosuke Kurokawa, researcher, Miz Company Limited
      • Yusuke Ichikawa, researcher, Miz Company Limited
      • Atsushi Maruyama, researcher, Miz Company Limited
      • Yoshiyasu Takefuji, Professor, Keio University

    Jocelyn Kaiser wrote an article entitled “The Alzheimer’s gamble” (1). Alzheimer’s investigators and researchers have being straying (1). Although the research grant has been increasing, there are no radical curatives for treating Alzheimer diseases so that patients and their families are lost in a maze. The there are three reasons why the pharmaceutical industry is giving up the search for an Alzheimer’s cure (2). The first is a complication of the disease itself: for years, it’s asymptomatic (2). The second is that there are no good methods to tell if someone has the early, biological stages of the disease (2). The problem of identifying the disease leads to the third hurdle: finding candidates for effective clinical trials (2).
    The bottleneck of drug-development processes is safety assurance. As long as safety assurance is satisfied and informed consents from patients and collaborations with their advocate are confirmed, we should lower the threshold for testing a variety of radical curatives. We must seriously think who will be suffering from losing the Alzheimer’s gamble.

    References:
    1. Jocelyn Kaiser, The Alzheimer's gamble, Science 31 Aug 2018: Vol. 361, Issue 6405, pp. 838-841
    2.https://qz.com/1282482/why-the-pharmaceutical-industry-is-giving-up-the-...

    Competing Interests: None declared.
  • RE: Evolutional advantages of Alzheimer´s disease

    As drying cone is throwing/distributing its seeds of biological information to its environment, the “drying” brain affected by Alzheimer´s disease (AD) first protects itself from contamination by new information and then distributes repetitively seeds of cultural information absorbed from its environment 50 years ago as a pleasure for the third generation, but as a harm for the second generation.

    Alzheimer’s disease is generally seen as an economical burden e.g. [1], but it can include some evolutional advantages, which could, I hope, be benefited by “the third generation” in the future, too.

    Reference
    1. Kaiser J (2018) The Alzheimer’s gamble: NIH tries to turn billions in new funding into treatment for deadly brain disease. Science Aug 30. DOI: 10.1126/science.aav2455

    Competing Interests: None declared.